[Medical Academy] CSCO Guidelines Upgrade: Dabrafenib Combined with Trametinib Becomes First-Line Class I Treatment Recommendation for BRAF-Mutant Advanced Non-Small Cell Lung Cancer – ByDrug

Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2. It inhibits cancer cell proliferation and metastasis by suppressing MEK protein activity and blocking the MAPK signaling pathway.

Dabrafenib is a BRAF inhibitor that specifically blocks the activity of BRAF protein, thereby inhibiting the proliferation and survival of tumor cells.

Dabrafenib is a BRAF inhibitor cancer drug, available as a mesylate. On May 29, 2013, the U.S. Food and Drug Administration (FDA) simultaneously approved the marketing applications of dabrafenib and trametinib. Dabrafenib is approved for the treatment of unresectable melanoma (tumors that cannot be surgically removed) and metastatic melanoma (tumors that have spread to other organs) harboring the BRAF V6 Chemicalbook00E mutation, but not for the treatment of wild-type BRAF melanoma. Mekinist is used to treat BRAF V600E or V600...

Trametinib is a MEK inhibitor with anticancer activity, inhibiting MEK1 and MEK2. It was approved for marketing by the U.S. Food and Drug Administration (FDA) in 2013. Abnormalities in the Ras/Raf/MEK/ERK signaling cascade are closely related to tumors. For example, mutations in BRAFV600 lead to persistent activation of this pathway. Trametinib mainly affects the MAPK signaling pathway by acting on MEK proteins, thereby inhibiting cell proliferation.